LeMaitre Vascular, Inc. (NASDAQ:LMAT) Receives Average Rating of “Moderate Buy” from Analysts

LeMaitre Vascular, Inc. (NASDAQ:LMAT) has received a consensus recommendation of “Moderate Buy” from the nine research firms that are currently covering the stock, Marketbeat reports. Two equities research analysts have rated the stock with a hold recommendation, six have given a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $94.57.

Several brokerages have issued reports on LMAT. Barrington Research boosted their price target on shares of LeMaitre Vascular from $92.00 to $93.00 and gave the company an “outperform” rating in a report on Friday. StockNews.com lowered shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Tuesday, August 27th. Cantor Fitzgerald began coverage on shares of LeMaitre Vascular in a report on Tuesday, October 15th. They issued a “neutral” rating and a $96.00 price target on the stock. JMP Securities upped their target price on shares of LeMaitre Vascular from $77.00 to $100.00 and gave the stock a “market outperform” rating in a report on Tuesday, August 20th. Finally, Oppenheimer reaffirmed an “outperform” rating and issued a $93.00 target price (up previously from $90.00) on shares of LeMaitre Vascular in a report on Friday.

LeMaitre Vascular Trading Up 7.3 %

Shares of LeMaitre Vascular stock opened at $94.88 on Friday. The firm has a fifty day simple moving average of $89.59 and a 200-day simple moving average of $83.11. LeMaitre Vascular has a 1-year low of $45.96 and a 1-year high of $101.67. The stock has a market capitalization of $2.13 billion, a price-to-earnings ratio of 51.85, a PEG ratio of 2.32 and a beta of 0.89.

LeMaitre Vascular (NASDAQ:LMAT) last released its earnings results on Thursday, October 31st. The medical instruments supplier reported $0.49 EPS for the quarter, beating the consensus estimate of $0.44 by $0.05. The firm had revenue of $54.82 million during the quarter, compared to analysts’ expectations of $53.50 million. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.39%. The business’s quarterly revenue was up 15.6% compared to the same quarter last year. During the same period in the prior year, the company earned $0.33 EPS. As a group, research analysts predict that LeMaitre Vascular will post 1.86 earnings per share for the current year.

LeMaitre Vascular Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 5th. Shareholders of record on Thursday, November 21st will be given a dividend of $0.16 per share. The ex-dividend date is Thursday, November 21st. This represents a $0.64 dividend on an annualized basis and a yield of 0.67%. LeMaitre Vascular’s payout ratio is presently 34.97%.

Insider Activity at LeMaitre Vascular

In related news, Director David B. Roberts sold 3,063 shares of the stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $82.07, for a total value of $251,380.41. Following the sale, the director now directly owns 14,114 shares in the company, valued at $1,158,335.98. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 10.79% of the stock is currently owned by corporate insiders.

Institutional Trading of LeMaitre Vascular

Several hedge funds have recently bought and sold shares of the stock. Summit Global Investments raised its holdings in LeMaitre Vascular by 2.4% during the 3rd quarter. Summit Global Investments now owns 6,192 shares of the medical instruments supplier’s stock worth $575,000 after buying an additional 146 shares during the period. Shaker Investments LLC OH grew its stake in shares of LeMaitre Vascular by 1.3% during the 2nd quarter. Shaker Investments LLC OH now owns 13,833 shares of the medical instruments supplier’s stock worth $1,138,000 after acquiring an additional 175 shares in the last quarter. NBC Securities Inc. grew its stake in shares of LeMaitre Vascular by 73.2% during the 3rd quarter. NBC Securities Inc. now owns 433 shares of the medical instruments supplier’s stock worth $40,000 after acquiring an additional 183 shares in the last quarter. GAMMA Investing LLC lifted its position in LeMaitre Vascular by 34.3% during the 3rd quarter. GAMMA Investing LLC now owns 736 shares of the medical instruments supplier’s stock worth $68,000 after buying an additional 188 shares in the last quarter. Finally, nVerses Capital LLC boosted its stake in shares of LeMaitre Vascular by 33.3% during the 2nd quarter. nVerses Capital LLC now owns 800 shares of the medical instruments supplier’s stock worth $66,000 after buying an additional 200 shares during the last quarter. 84.64% of the stock is currently owned by institutional investors and hedge funds.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.